These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22888604)

  • 1. Consistency as an alternative to potency testing.
    Duchow K
    Dev Biol (Basel); 2012; 134():119-22. PubMed ID: 22888604
    [No Abstract]   [Full Text] [Related]  

  • 2. Consistency as tool to support in vitro batch potency testing in GMP production.
    Stirling C
    Dev Biol (Basel); 2012; 134():115-8. PubMed ID: 22888603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potency testing of veterinary vaccines for animals: the way from in vivo to in vitro. Workshop summary.
    Dev Biol (Basel); 2012; 134():149-52. PubMed ID: 22888608
    [No Abstract]   [Full Text] [Related]  

  • 4. The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3Rs.
    De Mattia F; Chapsal JM; Descamps J; Halder M; Jarrett N; Kross I; Mortiaux F; Ponsar C; Redhead K; McKelvie J; Hendriksen C
    Biologicals; 2011 Jan; 39(1):59-65. PubMed ID: 21277791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards in vitro potency testing of inactivated erysipelas vaccines.
    Balks E; Wolf C; Loessner H; Werner E
    Dev Biol (Basel); 2012; 134():37-44. PubMed ID: 22888593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The validation of potency tests: hurdles identified by EMA/CVMP/IWP.
    Woodland R
    Dev Biol (Basel); 2012; 134():69-73. PubMed ID: 22888597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternatives to the use of animals in R & D and quality control of veterinary vaccines: an industry view.
    Verschueren C; Zänker S
    Dev Biol Stand; 1996; 86():49-51. PubMed ID: 8785991
    [No Abstract]   [Full Text] [Related]  

  • 8. Appropriateness of in vitro potency tests as a measure of vaccine or reference stability.
    Pfannenstiel MA; Inman M
    Dev Biol (Basel); 2012; 134():141-8. PubMed ID: 22888607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement, reduction or refinement of animal use in the quality control of veterinary vaccines: development, validation and implementation.
    van der Kamp MD
    Dev Biol Stand; 1996; 86():73-6. PubMed ID: 8785994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency testing of veterinary rabies vaccines: replacement of challenge by in vitro testing: considerations for development of alternative assays.
    Lewis CE; Fry AM; Hermann JR; Siev D; Dusek DM; Gatewood DM
    Dev Biol (Basel); 2012; 134():29-33. PubMed ID: 22888592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vaccines consistency approach project: an EPAA initiative.
    De Mattia F; Hendriksen C; Buchheit KH; Chapsal JM; Halder M; Lambrigts D; Redhead K; Rommel E; Scharton-Kersten T; Sesardic T; Viviani L; Ragan I
    Pharmeur Bio Sci Notes; 2015; 2015():30-56. PubMed ID: 26830158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential application of the consistency approach for vaccine potency testing.
    Arciniega J; Sirota LA
    Dev Biol (Basel); 2012; 134():135-9. PubMed ID: 22888606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro vaccine potency testing: a proposal for reducing animal use for requalification testing.
    Brown K; Stokes W
    Dev Biol (Basel); 2012; 134():75-81. PubMed ID: 22888598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency testing of veterinary vaccines: the way from in vivo to in vitro.
    Romberg J; Lang S; Balks E; Kamphuis E; Duchow K; Loos D; Rau H; Motitschke A; Jungbäck C
    Biologicals; 2012 Jan; 40(1):100-6. PubMed ID: 22075457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternatives to in vivo potency and protection tests for veterinary vaccines.
    Lucken RN
    Dev Biol Stand; 1999; 101():67-72. PubMed ID: 10566777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antigen measurement and potency tests: challenges encountered during method development...and lessons learned.
    Kubiak V
    Dev Biol (Basel); 2012; 134():83-91. PubMed ID: 22888599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in the replacement of animal experiments in the quality control of clostridial vaccines].
    Cussler K; Borrmann E; Werner E
    Dtsch Tierarztl Wochenschr; 2002 Apr; 109(4):172-7. PubMed ID: 11998369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress and future directions for reduction, refinement, and replacement of animal use in veterinary vaccine potency and safety testing: a report from the 2010 NICEATM-ICCVAM International Vaccine Workshop.
    Stokes WS; Kulpa-Eddy J; Brown K; Srinivas G; McFarland R
    Dev Biol (Basel); 2012; 134():9-21. PubMed ID: 22888590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.